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ABSTRACT Molecular modeling studies on antibody Fv regions have been pursued to design a second antigen-binding site
(X-site) in a chimeric single-chain Fv (xsFv) species of about 30 kDa. This analysis has uncovered an architectural basis
common to many Fv regions that permits grafting a X-site onto the Fv surface that diametrically opposes the normal
combining site. By using molecular graphics analysis, chimeric complementarity-determining regions (XCDRs) were defined
that comprised most of the CDRs from an antibody binding site of interest. The chain directionality of xCDRs was consistent
with that of specific bottom loops of the sFv, which allowed for grafting of XCDRs with an overall geometry approximating
CDRs in the parent combining site. Analysis of 10 different Fv crystal structures indicates that the positions for inserting
XCDRs are very highly conserved, as are the corresponding XCDR boundaries in the parent binding site. The results of this
investigation suggest that it should be possible to generally apply this approach to the development of chimeric bispecific
antibody binding site (XBABS) proteins.
INTRODUCTION
During the past decade considerable research has focused
on the Fv region of antibodies, a 25-kDa heterodimer of VH
and VL domains that form the antigen combining site. The
unique binding properties of a particular antibody derive
primarily from the structure of its complementarity-deter-
mining regions (CDRs), which comprise loops that connect
structurally conserved 13-strands forming the framework
regions of each variable domain. The inherent stability of
the framework region was first suggested by the process of
CDR grafting or humanization (Jones et al., 1986), in which
a hybrid Fv region may be genetically constructed by taking
the CDRs from a murine monoclonal antibody and grafting
them onto human framework regions (Jones et al., 1986;
Verhoeyen et al., 1988). During this early period in antibody
engineering, recombinant Fv fragments were produced as
discrete entities by secretion from bacteria (Skerra and
Plickthun, 1988; Field et al., 1988, 1990) or mammalian
cells (Reichmann et al., 1988), and Fv regions were suc-
cessfully engineered as the single-chain Fv (sFv), with both
variable domains connected by a linker peptide introduced
at the DNA level (Huston et al., 1988; Bird et al., 1988).
The present investigation has explored the possibility of
constructing a second binding site as an integral part the Fv
region (forming a XsFv), rather than making single-chain Fv
fusions with distinct protein domains, such as a radiometal
chelate (George et al., 1995), an Fc-binding protein (Tai et
al., 1990), or another sFv (Huston et al., 1991; Neri et al.,
1995). The minimal size of such bispecific Fv regions could
provide significant advantages in vivo, and this design of-
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fers an opportunity for allosteric linkage between pairs of
binding sites in a XsFv. The many examples of successful
CDR grafting (Adair, 1992) suggest that greater advantage
might be taken of the structural principles underlying the
process of humanization. For example, framework regions
(FRs) and CDRs may be viewed as separate contributors to
the Fv folding reaction, and a primary driving force in Fv
refolding could then be interpreted to involve the recovery
of FR interactions between ,B-strands linked by bottom
loops. As an alternative, the FRs could be defined to consist
of 13-strands connected by top loops, which include CDRs,
in which case the bottom loops could be considered avail-
able for the design of a second combining site. This reason-
ing led the present investigation to analyze Fv architecture
in search of a general strategy for changing the bottom
surface into a second combining site.
The secondary structure of immunoglobulin variable do-
mains has long been recognized to comprise a double layer
of 13-pleated sheets (Poljak et al., 1973), which may also be
viewed within the Fv region as two concentric 13-barrels
with the combining site formed by CDR loops mainly on the
inner barrel (Novotny et al., 1983). The extremely high
conservation of three-dimensional backbone architecture in
the Fv region was confmed by the first Fab crystal struc-
tures (reviewed by Amzel and Poljak, 1979), which also
suggested other invariant features of these structures (No-
votny et al., 1983; Novotny and Haber, 1985). A large
increase in the number of Fab crystal structures reported in
the literature has allowed the generalization of conserved Fv
structural features to an invariant coordinate system in
which the VH and VL are symmetrical about a twofold axis
(Gelfand et al., 1996). In the present investigation we have
discovered symmetry between binding site CDRs and the
bottom loops, which diametrically oppose the primary com-
bining site. Chimeric sFv (XsFv) designs were explored
using computer-generated models in which bottom loops
were altered to form a second binding site (Fig. 1, A and B).
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FIGURE 1 Schematic comparison of single-site sFv and dual-site XsFv,
with position of XCDRs indicated on linear map of the XsFv. (A) The
single-chain Fv is diagrammed as a VH-linker-VL molecule, with the linker
drawn diagonally across the face of the Fv region, connecting the C-
terminus of VH to the N-terminus of VL. (B) The chimeric single-chain Fv
(XsFv) analog is drawn to emphasize the twofold symmetry relating the
primary site (dotted surface) and the bottom X-site (solid black). The sFv
protein comprises about 250 amino acids with a molecular weight in the
range of 26,000-27,000, whereas the XsFv is slightly larger, with a
molecular weight that approaches 30,000. (C) The linear placement of
XCDRs in the XsFv gene or protein is dictated by bottom loop geometry,
which derives from the a-structure of each domain and the twofold
symmetry relating the VH and VL domains within the Fv region (Searle et
al., 1995). The order of the XCDRs (H3', Hi', H2', L3', Li', L2') contrasts
with that of the normal CDRs (HI, H2, H3, Li, L2, L3).
Within limits, it was found that much of the CDR structure
from a typical binding site could be positioned on the
bottom of the Fv in a nearly normal configuration, although
XCDRs were grafted onto the FRs out of the normal order
seen with CDRs (Fig. 1 C). Discussions of a second binding
site in the Fv have previously been incidental to meeting
presentations (Keck et al., 1994; Huston et al., 1994; Hus-
ton, 1994) and have appeared in a related patent application
(Huston and Keck, 1993).
MATERIALS AND METHODS
The Fv coordinates used for molecular modeling were obtained from the
Protein Data Bank (PDB) of the Brookhaven National Laboratory (Bern-
stein et al., 1977). These studies utilized the following Fab structures (with
the corresponding PDB data set identified in parentheses): anti-phospho-
choline McPC603 (2MCP); anti-digoxin 26-10 (1IGJ); anti-lysozyme D1.3
(IFDL); KOL (2FB4); anti-fluorescein 4-4-20 (4FAB); anti-lysozyme;
HyHEL-5 (2HFL); anti-lysozyme HyHEL-10 (3HFM); anti-galactan J539
(2FBJ); anti-p-azobenzenearsonate R19.9 (IF19); anti-neuraminidase
NC41 (lNCA).
Source XCDR sequences consist of the portion of each CDR that can be
grafted into bottom loop positions defined by splice points. Target seg-
ments are the bottom loop sequences that would be displaced in the
grafting process; the boundaries of the target segments are the target XCDR
splice points of a XBABS protein. Flanking the first and last residues of
each source or target sequence, the splice points are each defined as the
midpoint between the a-carbons of a given end-point residue and its
adjacent flanking residue (the residue preceding the XCDR or target seg-
ment's amino terminus or following its carboxyl terminus). The first three
data sets were used for superposition models of the XsFv, and all 10
structures were used to calculate average XCDR source and target splice
points.
Model building
Molecular modeling was conducted on either a Silicon Graphics Indigo II
or 4D/70 GT graphics workstation. Aside from the SUPER algorithm for
superposition of multiple Fv structures, which was written for this study
(Keck, unpublished), all modeling utilized the INSIGHT and HOMOL-
OGY protein modeling packages (Molecular Simulations, San Diego, CA).
The HOMOLOGY program was used in the construction of XsFv models
and in the examination of specific molecules to correlate protein sequence
with structure. To create a XsFv model, the carboxyl-terminal end of H2'
was fused with the amino-terminal end of the interdomain linker, consist-
ing of a (Ser4-Gly)3 type of linker (Adams et al., 1993; McCartney et al.,
1995; Tai et al., 1995; Huston et al., 1996b) or (Gly4-Ser)3 linker (Huston
et al., 1988; Tai et al., 1990), as well as others in the literature (reviewed
by Huston et al., 1991, 1996a).
Structure alignment
For superposition models, manual alignment of pairs of Fv structures was
accomplished using the INSIGHT program to display the a-carbon back-
bones of the source and target structures. The CDR loops of the source
structure were aligned with the bottom loops of the target structure. The H3
and L3 CDR loops (H TL4 and L TL4, respectively) of the source structure
were respectively aligned with bottom loops H BL2 and L BL2 of the
target structure (Fig. 2). Small translations and rotations then resulted in the
optimal alignment of HI (H TLI) with H BL4 and Li (L TLI) with L BL4.
Finally, the H IS2 strand from the source structure was optimally aligned
with H IS4 from the target structure, and L IS2 was aligned with L IS4.
The MCP/MCP superposition model yielded the splice points for
McPC603, and splice points for the other nine Fv fragments were based on
homology with the MCP/MCP model. The source or target splice points of
all 10 Fv structures were superimposed. The program SUPER, written in
Microsoft C to run on personal computers under DOS, optimized the
three-dimensional alignment of multiple sets of corresponding points. For
each Fv structure, the MCP/MCP homology positions were used to identify
two point sets, comprising the 10 splice points for source XCDRs (H3n,
H3c, Hln, Hlc, H2n, L3n, L3c, Lln, Llc, L2n) and 10 splice points for
target segments (H3'n, H3'c, Hl'n, Hl'c, H2'n, L3'n, L3'c, Ll'n, Ll'c,
L2'n). Point groups were then formed, each consisting of the correspond-
ing point from all 10 structures (e.g., each Fv contributed the coordinates
of its H3n splice point to form the H3n point group). A central point
(average splice point) was defined for each point group by averaging the
coordinates for members of that group. Averaging of the 10 groups of
source splice points yielded one set of average source splice point values,
and a corresponding set of average target splice points was similarly
calculated.
The average source and target splice points were then aligned by
SUPER to compare their relative geometries. Aliganent of the 10 Fv
structures was achieved by linking each central point to each point in a
group by a first-order force or "spring." For each point set from a specific
Fv structure, the net translational force and torque on that set resulting from
the net force of the "springs" was calculated, and the point set was
translated and rotated by an amount proportional, respectively, to the net
force and torque. Within a point group, the mean square distance between
individual points and the average central point was calculated, and, after
each iteration of translation and rotation, its sum over all of the groups was
calculated as a measure of the overall alignment. The alignment process
was stopped when additional iterations changed these sums by less than
10-5 A2. The average radial distribution of end points around the center
point of a given point group was calculated as a measure of the compact-
ness of a point group's spatial distribution. Source and target vectors were
defined as pointing from the amino- to the carboxyl-terminal splice points
for H ', H3', Li', and L3', and vectors were presented in three dimensions
by using stereo diagrams.
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FIGURE 2 A backbone model of the VH domain
showing bottom loop positions suitable for ACDR graft-
ing. The protein architecture that underlies the XsFv
design is suggested in this schematic. This diagram
depicts the D1.3 VH a-carbon backbone based upon
crystallographic coordinates for the Fv region of Dl.3
Fab, from data set 1FDL in the Protein Data Bank
(PDB) of Brookhaven National Laboratory (Bernstein et
al., 1977). The 13-strands are drawn as ribbons in this
diagram, which is based on the crystal structure of the
anti-lysozyme D1.3 Fab fragment (Fischmann et al.,
1991). The primed loop notations indicate target sites
where VCDRs would be grafted onto bottom loops of
the VH domain.
The variable region amino terminus (N-t) and car-
boxyl terminus (C-t) are noted on VH. Loops in this
figure are denoted as top loops (TL) and bottom loops
(BL), which correspond to front and back loops, respec-
tively, as defined by Amzel and Poljak (1979); 13-strands
correspond to the definition of structurally conserved
regions (Greer, 1991), being common to all aligned
structures. The CDRs (curved lines in three shades of
blue) are part of top loops that connect ,B-strands (rib-
bons); bottom loops are represented by connections be-
tween a-carbons, noted as BL1-4.
The gray ribbons indicate that 1-strands are normally
buried at the interface between VH and VL domains in
the sFv, and white ribbons indicate surface-exposed
13-structure. OS, outer strand; IS, inner strand; TL, top
loop; BL, bottom loop; N-t, amino terminus; C-t, car-
boxyl terminus; HI, H2, and H3, normal CDRs; Hi'
(lavender), H2' (green), or H3' (copper-brown), target
segments, defined as the residues on the bottom of the
Fv that will be displaced by VCDRs.
RESULTS
Symmetry and design of a XsFv
The general relationship between an sFv and a XsFv is
suggested by the schematic diagrams in Fig. 1, A and B.
Examination of the bottom loop arrangement in McPC603
revealed that certain combinations of loops displayed a
geometric relationship that was very similar to that of the
original CDRs in the McPC603 combining site. In an anal-
ysis described at the end of this section, these observations
were found to hold true for 10 different crystal structures of
Fv regions available in the PDB. Bottom loops that might be
used to graft modified CDRs onto the Fv were identified by
molecular modeling. As a manifestation of the complex
Greek key fold of the ,B-strands in the variable regions
(Searle et al., 1995), these chimeric CDRs (XCDRs) mapped
onto the linear XsFv sequence in the order H3', H', H2',
L3', L1', and L2' (Fig. 1 C).
Spatial positions of bottom VH loops that would be mod-
ified in the process of grafting XCDRs may be visualized in
Fig. 2. Using a nomenclature based on the structural ho-
mology of Ig variable domains (Huston et al., 1993a,b), the
diagram indicates where the H3' and Hi' regions would be
positioned, respectively, in the BL2 and BL4 bottom loops
and adjacent inner ,B-strands. The position of the C-terminal
XVH
N-t
I
H3' Hl1' H2I
H2' is indicated by the green coloration of the final stretch
of IS4, but H2' would actually continue beyond the end of
VH, with extra residues fused to the linker of a XsFv. If VL
were drawn beside Fig. 2, its framework and bottom loop
structures would be essentially the same as those of the VH
schematic. The design of a corresponding XVL would thus
involve the bottom loops positioned as in XVH, but they
would be labeled L3', Li', and L2'. In a XsFv configured as
XVH-linker-XVL, the final residues of L2' would lack a
fixed C-terminus unless they were attached artificially to the
framework, for example by disulfide bonding through a pair
of cysteinyl residues engineered at appropriate positions.
Structural considerations in XCDR grafting
Our initial XsFv modeling studies were conducted using
the 2MCP coordinates for the Fv region of McPC603
Fab, the anti-phosphorylcholine Fab fragment first solved
by Segal et al. (1974) and brought to higher resolution by
Satow et al. (1986). To determine the positions where
XCDR loops may be appropriately grafted onto the bot-
tom framework (defined as splice points), we initially
embarked on building a model of McPC603 XsFv with
McPC603 XCDRs grafted onto the bottom of the
McPC603 sFv (defined as MCP/MCP XsFv). Two copies
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FIGURE 3 Molecular models showing splice point
geometry in McPC603 Fv and MCP/MCP XsFv, em-
phasizing the twofold symmetry of binding sites in the
XsFv. (A) Visual definition of the target splice sites
identified in the McPC603 Fv. Stereo backbone dia-
grams of McPC603 Fv drawn to show the positions of
its XCDR splice sites. The bottom loop geometry of
each variable domain provides potential sites for graft-
ing xCDRs H3', L3', Hi', and Li' in a reasonable
spatial approximation of the CDR loops that are most
central to the original binding site. The McPC603
XCDR loops were grafted onto bottom framework po-
sitions, as indicated by vectors drawn approximately
between the fixed endpoints (pointing from N- to C-
terminal positions flanking XCDR residues) that are
compatible with the normal chain directionality of
XCDRs 1 and 3 in the context of the binding site.
(B) The resulting XsFv constructed computationally by
grafting the McPC603 XCDRs into the defined target
splice points. This computer-generated molecular
model of a XsFv represents a bivalent analog of the
McPC603 sFv, in which the tCDRs from the natural
phosphocholine-binding site on top have been trans-
planted to bottom loop positions.
In addition to the loops altered as noted in A, the
remaining two XCDRs based on H2' and L2' were
positioned with only their N-terminal ends fused ge-
netically to rigid framework positions, at splice points
noted in A of this figure; the C-terminus of H2' was
fused to the linker, and the C-terminus of L2' was
affixed to the VL surface with a disulfide bond between
a carboxyl-terminal cysteinyl residue and surface Cys
mutation at L5.
The two binding sites are related by an approximate
twofold axis passing through the molecule from left to
right. The red loops are the original CDRs, the copper
loops are added XCDRs, the blue strands are frame-
work regions, the light blue line is the linker, and the
yellow balls are sulfur atoms, two in each domain
forming the buried disulfide bond.
of McPC603 Fv were aligned, one with its binding site
pointed upward and the other with its bottom surface
upward. The heavy- and light-chain CDR loops of one
structure were thus superimposed, respectively, on the
heavy- and light-chain bottom loops of the other structure
to give the greatest overall coincidence of the top and
bottom loops. Splice points were chosen for grafting
chimeric CDRs (XCDRs) using the following three cri-
teria: 1) retain as much of the CDR sequence as possible;
2) preserve framework residue positions that are judged
to be critical to the structural integrity of the V domain;
3) achieve optimal superposition of the a-carbon back-
bone in regions of source and target splice points.
From this superposition model we identified the CDR res-
idues that were to be inserted (source ACDRs) and the frmne-
work residues that would be displaced (target sequences). The
positions of target splice points for McPC603 Fv are displayed
in a stereo diagram (Fig. 3 A), which indicates where the
McPC603 XCDRs were grafted to produce the MCPIMCP
XsFv, displayed in Fig. 3 B. The splice points in Fig. 3 A have
been connected, defining a vector for each x-loop with fixed
end points, to make their geometric relationship more readily
apparent; the vectors point from the N- to C-terminal splice
points for each target segment. It is apparent in the MCP/MCP
XsFv structure that the nonnal shape of CDRs on the top is
closely mimicked by yCDRs configured on the bottom. The
two binding sites are related by an approximate twofold axis
that runs horizontally through the molecule, as drawn. In this
model, the L2' loop has been given a fixed end point at its
C-terminus by adding a C-terminal Cys residue that can disul-
fide bond with an opposing Cys added at residue L5 in the OS1
,3-strand.
Generally, a given XCDR sequence represents a subset of
its parent CDR sequence as an outgrowth of several design
A Antigen Antigen
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criteria: 1) the relative shapes of the top and bottom loops,
2) the actual positions of splice overlap, and 3) the structural
limits on the alteration of bottom loop sequences. The result
of these considerations can be seen by comparing the se-
quences of MCP/MCP XsFv and McPC603 sFv, which are
presented at the top of Fig. 4. Structurally aligned sequence
positions for CDRs and XCDRs are also listed in Table 1, in
columns labeled MCP/MCP. Binding site geometry is con-
served in part by interchain hydrogen bonding between
glutamine residues (Novotny and Haber, 1985) that are
amino-terminal to H3' and L3' (Gln H39 and Gln L45 by
structural homology (Figs. 4 and 5) equivalent to H39 and
L38 according to Kabat et al., 1991). Likewise, there are
important electrostatic contributions from the aspartate res-
idues amino-terminal to HI' and Li' (Asp H92 and Asp
L89, or H86 and L82 according to Kabat), which form
intrachain salt bridges with Arg or Lys at positions H69 and
L68, respectively (H66 and L60 according to Kabat).
Modeling of XBABS proteins by homology with
structurally aligned sequences
It should be possible to generalize the XsFv design from the
MCP/MCP model to other Fv regions and X-site combina-
tions, by virtue of the strong structural conservation and
sequence homology among V regions. Sequence alignment
by structural superposition (discussed previously by Huston
et al., 1993a,b) provides a mechanism for using homology
in the design of XBABS proteins. In our analysis, sequences
were aligned with the HOMOLOGY program by superim-
posing the three-dimensional a-carbon backbone of the
given Fv structure on that for McPC603 Fv. Structurally
homologous regions identified for the sequences in Figs. 4
and 5 correspond to the structural designations noted on the
VH schematic of Fig. 2. Using the MCP/MCP XsFv design,
the homology-based source and target XCDR sequences of
nine other representative Fv fragments were identified, and
their structurally aligned V domain sequences are given in
Fig. 5. Sequence positions are noted for their XCDR se-
quences on the Source line and for their target segments
(bottom loop sequences to be displaced) on the Target line.
As a test of the homology modeling approach, we com-
pared a 26-10/D1.3 XsFv superposition model with its ho-
mology model (its sequence in Fig. 4 is based upon the
MGP/MCP model). The anti-digoxin 26-10 Fv sequence
TABLE I Comparison of MCP/MCP and 28-10/D1.3 XsFv
superposition splice points
Target splice points Source splice points
x-Loop MCP/MCP 26-10/Di.3 MCP/MCP 26-10/D1.3
H3' H40-H46 H39-H47 H102-H116 H101-H 17
HI' H93-H95 H93-H95 H31-H33 H30-H33
H2' H122 H122 H51-H72 H51-72
L3' L46-L52 L46-L52 L1OI-L106 L101-L106
LI' L91-L92 L91-L92 L30-L39 L31-L39
L2' L109 L109 L56-L68 L55-L65
was structurally aligned using the PDB coordinates for the
IIGJ structure of 26-10 Fab (Jeffrey et al., 1993), and the
D1.3 sequence was aligned using the 1FDL structure of
D1l.3 (Satow et al., 1986). Sequence homology with the
MCP/MCP superposition model was used to design the
26-10/D1.3 XsFv, in which all six D1.3 xCDRs were grafted
onto the 26-10 sequence (Fig. 4). The 26-10 and D1.3
structures were also used to determine the x-loop splice
points by superposition of computer-generated models of
the two Fv regions (identified in Table 1 in the columns
labeled 26-lOID1.3). The resulting source and target bound-
aries (Table 1, listed in terms of residue positions in the
aligned sequences) were found to be nearly the same as
those based on sequence homology (Table 1, columns la-
beled MCP/MCP). Only small differences in splice points
were found between the XsFv models derived by homology
and superposition, which supports the use of homology-
based models as reasonable first approximations for XBABS
design.
Generality of splice point geometry
The rationale for using homology-based splice points for the
boundaries of XCDRs and their target segments was tested
further through computational analysis of representative Fv
crystal structures. A necessary condition for the use of
generalized splice points is that their geometry should be
highly conserved across many Fv structures, for both the
source VCDR and target splice points. Average source and
target splice points should likewise be in close proximity
when they are superimposed. We have compared the actual
coordinates for the standard MCP/MCP splice positions
among 10 Fv regions of known structure (see Materials and
Methods). Averaging each group of homologous splice
points gave 10 average splice points for the source and 10
for the target. For each XCDR with two fixed end points
(HI', H3', Li', L3'), a vector has been drawn from the
amino-terminal to the carboxyl-terminal splice point, and
pairs of related source and target XCDR vectors were com-
pared (e.g., Hi from source and HI' from target positions).
These data were presented in a stereo vector diagram (Fig.
6), showing that the source and target vectors are very close,
and hence that the geometries of source and target splice
sites are indeed very similar.
A numerical comparison of splice site positions is given
in Table 2, which indicates that the distances between
average source and target positions are in most cases no
greater than the error typical of atomic coordinates reported
for protein crystal structures. The Source and Target col-
umns labeled Group Radius list, for each point group, the
average radial distance between the 10 actual points and
single average point for that group. The low values of these
radii further emphasize the compactness of these splice
point distributions. It is apparent that target end points from
the bottom loops of the framework architecture show a
smaller variation from the average than do source splice
points. The striking compactness of each point group's
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FIGURE 5 Structural alignment of VH and VL sequences of Fv structures from the PDB, showing the xCDRs defined by homology with the MCP/MCP
model. The labels for structural elements shown in Fig. 2 and defined in the legend to Fig. 4 are used here to relate the structurally aligned sequences of
these 10 Fv regions with known crystal structures (PDB data sets utilized are listed in Materials and Methods). The HOMOLOGY program was used to
align the a-carbon backbone of each variable domain structure with the McPC603 VH and VL reference structures.
spatial distribution was indicated by calculations of the groups, the sums of source and target group radii were
distances between corresponding average source and target greater than the distance between the average source and target
points, listed in the right column of Table 2. For some point points for those groups, which further underscores the similar-
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FIGURE 6 Vector diagram in 3-space that compares the average geometry of splice sites for source and target segments, based on 10 Fv crystal structures.
The source and target XCDR vectors connect the average splice points (from N- to C-terminal sequence positions), as defined in Materials and Methods.
The SUPER algorithm was used to align the source and target splice points for all 10 Fv structures. The averages of the resulting point sets defined central
points that were plotted to make this stereo diagram, using the SUPER algorithm to superimpose the averaged source and target sets of splice points. Labels
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a XsFv in the XVH-linker-XVL configuration, positioned approximately as in Fig. 3 with the X-site facing downward. The average source vectors were
superimposed by effectively rotating the primary binding site (on top in Fig. 3) to face downward in alignment with the X-site. The approximate ends of
the vectors are shown in the MCP/MCP XsFv ribbon diagram (Fig. 3) as the junctions between blue framework and copper-brown XCDRs, connected so
that vectors always point from N- to C-terminal points. These general vectors contrast with those drawn in Fig. 3 A, which are the target vectors of the
MCP/MCP model, displayed in the context of the McPC603 Fv a-carbon backbone structure.
ity of average target and source splice point geometry. All of
these X-site comparisons involved the mapping of VH source
XCDRs to VH target segments and, similarly, the mapping of
VL source to VL target sequences. However, the twofold sym-
metry of the V domains permits an alternative mapping
scheme, of XVH source to XVL target and XVL source to XVH
target. Vector pairs for this alternative XBABS model were
calculated using the same set of Fv structures (data not shown),
and the average of the distances between corresponding target
and source points was 2.25 A, which was only slightly greater
than the 1.33 A calculated for the homologous mapping case
(based on data in Table 2).
DISCUSSION
This investigation has uncovered previously unrecognized
symmetry properties that apply to binding-site CDRs and
bottom loops of the Fv region. Analysis of the correspond-
ing homology-based splice points in 10 Fv structures has
revealed that their source and target positions are conserved
to a remarkable degree. These architectural considerations
suggested a rationale for the construction of a second bind-
ing site that relies on XCDR grafting to preform a binding
site surface on the bottom of the Fv region, which would
thereby predispose the X-site to recognition of a given
antigenic epitope. Phage antibody display libraries represent
an analogous situation, in that they depend upon the pre-
formed binding site surfaces that result from combinatorial
pairing of VH and VL genes (Winter et al., 1994).
The utility of the molecular designs developed in this
investigation will ultimately depend on the ability of
XBABS proteins to refold. This appears to be practical,
based on promising results in our preliminary experiments
(Keck et al., 1994; Tai et al., unpublished results). Another
facet of XBABS stability involves the interaction between
XVH and XVL domains. The CDRs of a normal Fv region
account for about 25% of the contact surface between the
VH and VL domains (Huston et al., 1991), and thus changes
in CDRs could significantly modulate the associative inter-
actions between a given pair of variable domains (Huston et
al., 1 996a). Although contributing a smaller fraction of
interdomain contacts, the x-loops of a XBABS protein could
have a similar impact on heterodimer stability. For example,
insertion of XCDRs could enhance the association of het-
erodimers, making a stable XFv practical. Alternatively,
there might be a negligible impact, or the XCDRs could
lower the association constant of the original V domains,
which might be offset by the construction of a XsFv.
TABLE 2 Differences between average source and target positions with group radii of splice points
Source Target
Distance (A) between average source and
Point group Group radius (A) Group radius (A) Point group target point group positions
H3n 1.04 0.48 H3'n 1.85
H3c 0.63 0.49 H3'c 1.11
HIn 0.98 0.48 H I'n 2.76
Hlc 0.71 0.30 H I'c 1.08
H2n 0.66 0.39 H2'n 0.23
L3n 1.45 0.35 L3'n 1.10
L3c 0.53 0.37 L3'c 0.57
Lln 1.01 0.42 Litn 2.15
LIc 0.87 0.22 LI'c 0.73
L2n 0.72 0.40 L2'n 1.67
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The development of XBABS proteins also relates to more
general areas of de novo protein design, particulary those
that have sought to explain how the composition of turns
(Brunet et al., 1993; Predki et al., 1996) and periodicity of
sequence (Kamtekar et al., 1993; Kamtekar and Hecht,
1995; Xiong et al., 1995) affect the recovery and stability of
specific secondary structures such as 3-sheet (Hecht, 1994).
Betadoublet is a recombinant protein that folds spontane-
ously to dimerize as a (3-sandwich (Quinn et al., 1994), and
betabellin is a synthetic, cysteine-containing protein analog
that folds into a (3-sandwich only after the formation of
interchain disulfide bonds (Yan and Erickson, 1994). Pro-
teins based on periodic sequence have also been described
that rely on designing the antisense or complementary pro-
teins that can be defined by a reversed reading of a given
mRNA (Clarke and Blalock, 1990; Blalock, 1994).
Framework engineering of the Fv region has in the past
focused primarily on humanization and the idealization of
framework properties, or improvement of antigen binding.
Thus the improvement of folding and production yields
through framework mutations has thus far involved residues
located in FRI (McCartney et al., 1995) or in FR2 (Knappik
and Pluckthun, 1995). The VH framework of the B1-8
antibody tolerated the insertion of four residues in its non-
CDR TL3 top loop, adjacent to the antibody combining site
(Simon and Rajewsky, 1992). Normal hapten binding was
recovered in this analog, and the authors proposed that this
top loop might be used as a fourth CDR to increase contact
with antigen beyond that normally possible. The Fv region
of antibodies has also been used as a recombinant carrier of
loop peptides. These so-called antigenized antibodies have
been made by substituting an antigenic loop sequence for a
CDR (reviewed by Billetta and Zanetti, 1993); related work
has been reported on sequence substitutions in the top loops
of the CH' constant region (Sandlie et al., 1996).
The results of the present investigation suggest how
XBABS proteins might be optimized by phage display tech-
niques. For instance, the refinement process of a XBABS
protein could involve site-directed or cassette mutagenesis
of given loops in a XsFv, followed by phage display and
antigen-driven selection. More extensive application of
these techniques to XBABS construction could take full
advantage of the homology-based design process delineated
in this study. The insertion of randomly synthesized XCDRs
that span the predicted pairs of splice points for target
segments in an sFv gene would lead to a XsFv mutant
library wherein all species would have the same primary
combining site but a large population of different X-site
configurations. Appropriate selection by conventional
phage display library methods could yield the desired com-
bination of binding-site activities. Selection with and with-
out antigen bound to the primary site could allow selection
of variants that exhibit a range of allosteric properties.
Future investigations are expected to pursue the construc-
tion of XBABS proteins with specific Fv regions by using
the highly sophisticated methods of antibody engineering
(Borrebaeck, 1995; Huston et al., 1996a). Successful imple-
mentation of designs suggested by this paper would have
important clinical ramifications, for instance, in the devel-
opment of minimal bispecific antibody species for cancer
therapy. Furthermore, XBABS designs that exhibit signifi-
cant allosteric linkage between sites would offer entirely
novel opportunities for the development of unique therapeu-
tic agents, homogeneous immunoassays, and allosteric cat-
alytic antibodies.
We (P. C. Keck, M.-S. Tai, C. Cohen, and J. S. Huston) thank Professor
Timasheff for over a decade of his advice and enthusiasm, which have
added immeasurably to our research in protein and antibody engineering.
As protein physical chemists, we have been inspired throughout our careers
by the beauty and inexhaustible creativity of his thermodynamic studies on
protein interactions and cosolvent effects, as well as the rigor, clarity, and
eloquence of his research papers.
This research project was stimulated by an SBIR grant (R43 CA52323)
from the National Cancer Institute. In addition, we are grateful to Charles
Cohen for his encouragement and support.
REFERENCES
Adair, J. R. 1992. Engineering antibodies for therapy. Immunol. Rev.
130:5-40.
Adams, G. P., J. E. McCartney, M.-S. Tai, H. Oppermann, J. S. Huston, W.
F. Stafford III, M. A. Bookman, I. Fand, L. L. Houston, and L. M.
Weiner. 1993. Highly specific in vivo tumor targeting by monovalent
and divalent forms of 741F8 anti-c-erbB-2 single-chain Fv. Cancer Res.
53:4026-4034.
Amzel, L. M., and R. J. Poljak. 1979. Three-dimensional structure of
immunoglobulins. Annu. Rev. Biochem. 48:961-997.
Bernstein, F. C., T. F. Koetzle, G. J. B. Williams, E. F. Meyer, M. D. Brice,
J. R. Rodgers, 0. Kennard, T. Shimanouchi, and M. J. Tasumi. 1977.
The protein data bank: a computer-based archival file for macromolec-
ular structures. J. Mol. Bio. 112:535-542.
Billetta, R., and M. Zanetti. 1993. Antigenicity and immunogenicity of
antigenized antibodies. Studies on B and T cells. "Antibody Engineer-
ing. Medical Applications," ed. by M. Zanetti. Int. Rev. Immunol.
10:251-263.
Bird, R. E., K. D. Hardman, J. W. Jacobson, S. Johnson, B. M. Kaufman,
S.-M. Lee, T. Lee, S. H. Pope, G. S. Riordan, and M. Whitlow. 1988.
Single-chain antigen-binding proteins. Science. 242:423-426.
Blalock, J. E. 1994. Protein configurations. Science. 265:1511.
Borrebaeck, C., editor. 1995. Antibody Engineering, 2nd ed. Oxford Uni-
versity Press, New York and Oxford.
Brunet, A. P., E. S. Huang, M. E. Huffine, J. E. Loeb, R. J. Weltman, and
M. H. Hecht. 1993. The role of turns in the structure of an a-helical
protein. Nature. 364:355-358.
Clarke, B. L., and J. E. Blalock. 1990. Steroidogenic activity of a peptide
specified by the reversed sequence of corticotropin mRNA. Proc. Natl.
Acad. Sci. USA. 87:9708-9711.
Field, H., G. T. Yarranton, and A. R. Rees. 1988. Vaccines (Cold Spring
Harbor). 88:29-34.
Field, H., G. T. Yarranton, and A. R. Rees. 1990. Expression of mouse
light and heavy chain variable regions in Escherichia coli and reconsti-
tution of antigen-binding activity. Protein Eng. 3:641-647.
Fischmann, T. O., G. A. Bentley, T. N. Bhat, G. Boulot, R. A. Mariuzza,
S. E. V. Phillips, D. Tello, and R. J. Poljak. 1991. Crystallographic
refinement of the three-dimensional structure of the FabD1.3-lysozyme
complex at 2.5 A resolution. J. Biol. Chem. 266:12915-12920.
Gelfand, I. M., A. E. Kister, and D. Leshchiner. 1996. The invariant system
of coordinates of antibody molecules: Prediction of the "standard" C'
framework of VL and VH domains. Proc. Natl. Acad. Sci. USA. 93:
3675-3678.
George, A. J. T., F. Jamar, M.-S. Tai, B. T. Heelan, G. P. Adams, J. E.
McCartney, L. L. Houston, L. M. Weiner, H. Oppermann, A. M. Peters,
Keck and Huston XBABS Dual Binding Site Fv 2011
and J. S. Huston. 1995. Radiometal labeling of recombinant proteins by
a genetically engineered, minimal chelation site: technetium-99m coor-
dination by single-chain Fv antibody fusion proteins through a C-
terminal cysteinyl peptide. Proc. Natl. Acad. Sci. USA. 92:8358-8362.
George, A. J. T., J. A. Titus, C. R. Jost, I. Kurucz, P. Perez, S. M. Andrew,
P. J. Nicholls, J. S. Huston, and D. M. Segal. 1994. Redirection of T
cell-mediated cytotoxicity by a recombinant single-chain Fv molecule.
J. Immunology. 152:1802-1811.
Greer, J. 1991. Comparative modeling of homologous proteins. Methods
Enzymol. 202:239-252.
Hecht, M. H. 1994. De novo design of ,8-sheet proteins. Proc. Natl. Acad.
Sci. USA. 91:8729-8730.
Huston, J. S. 1994. Engineering single-chain Fv species with dual com-
bining sites: covalent (sFv')2 dimers and chimeric bispecific antibody
binding sites (XBABS). Fifth IBC International Conference on Antibody
Engineering: New Technologies, Applications and Commercialization,
La Jolla, CA, December 7-9.
Huston, J. S., and P. Keck. 1993. Chimeric multivalent protein analogues
and methods of use thereof. Patent Cooperation Treaty WO 93/23537.
Huston, J. S., P. Keck, M.-S. Tai, D. Jin, J. McCartney, W. F. Stafford III,
M. Mudgett-Hunter, H. Oppermann, and E. Haber. 1993a. Single-chain
immunotechnology of Fv analogues and fusion proteins. In Immuno-
technology, J. Gosling and D. Reen, editors. Portland Press, London.
47-60.
Huston, J. S., D. Levinson, M. Mudgett-Hunter, M.-S. Tai, J. Novotny, M.
N. Margolies, R. J. Ridge, R. Bruccoleri, E. Haber, R. Crea, and H.
Oppermann. 1988. Protein engineering of antibody binding sites: recov-
ery of specific activity in an anti-digoxin single-chain Fv analogue
produced in E. coli. Proc. Natl. Acad. Sci. USA. 85:5879-5883.
Huston, J. S., M. N. Margolies, and E. Haber. 1996a. Antibody binding
sites. Adv. Protein Chem. 49:327-447.
Huston, J. S., M. Mudgett-Hunter, M.-S. Tai, J. E. McCartney, F. D.
Warren, E. Haber, and H. Oppermann. 1991. Protein engineering of
single-chain Fv analogues and fusion proteins. Methods Enzymol. 203:
46-88.
Huston, J. S., H. Oppermann, and S. N. Timasheff. 1996b. Serine-rich
peptide linkers. U.S. Patent 5,525,491 (June 11, 1996).
Huston, J. S., M.-S. Tai, J. E. McCartney, P. Keck, and H. Oppermann.
1993b. Antigen recognition and targeted delivery by the single-chain Fv.
Cell Biophys. 22:189-224.
Huston, J. S., M.-S. Tai, W. F. Stafford III, H. Oppermann, and P. Keck.
1994. Chimeric bispecific antibody binding sites (XBABS): 30 kD
single-chain Fv proteins with dual binding sites. 11th International
Hammersmith Meeting, Advances in the Applications of Monoclonal
Antibodies in Clinical Oncology, Molyvos, Lesvos, Greece, May 23-26.
9.
Jeffrey, P. D., R. K. Strong, L. C. Sieker, C. Y. C. Chang, R. L. Campbell,
G. A. Petsko, E. Haber, M. N. Margolies, and S. Sheriff. 1993. 26-10
Fab-digoxin complex: affinity and specificity due to surface comple-
mentarity. Proc. Natl. Acad. Sci. USA. 90:10310-10314.
Jones, P. T., P. H. Dear, J. Foote, M. S. Neuberger, and G. Winter. 1986.
Replacing the complementarity-determining regions in a human anti-
body with those from a mouse. Nature. 321:522-525.
Kabat, E. A., T. T. Wu, H. M. Perry, K. S. Gottesman, and C. Foeller.
1991. Sequences of Proteins of Immunological Interest, 5th ed. Publi-
cation No. 91-3242. U.S. Department of Health and Human Services,
Public Health Service, National Institutes of Health, Bethesda, MD.
Kamtekar, S., and M. H. Hecht. 1995. The four-helix bundle: what deter-
mines a fold? FASEB J. 9:1013-1022.
Kamtekar, S., J. M. Schiffer, H. Xiong, J. M. Babik, and M. H. Hecht.
1993. Protein design by binary patterning of polar and nonpolar amino
acids. Science. 262:1680-1685.
Keck, P. C., M.-S. Tai, H. Oppermann, and J. S. Huston. 1994. Chimeric
bispecific antibody binding sites (XBABS): design of a second combin-
ing site within the Fv region and recovery of single-chain Fv binding
activity after integration of new binding loops between /3-strands of V
domains. Biophys. J. 66:A431.
Knappik, A., and A. Pluckthun. 1995. Engineered turns of a recombinant
antibody improve its in vivo folding. Protein Eng. 8:81-89.
McCartney, J. E., M.-S. Tai, R. M. Hudziak, G. P. Adams, L. M. Weiner,
D. Jin, W. F. Stafford III, S. Liu, M. A. Bookman, A. A. Laminet, I.
Fand, L. L. Houston, H. Oppermann, and J. S. Huston. 1995. Engineer-
ing disulfide-linked single-chain Fv dimers [(sFv')2] with improved
solution and targeting properties. Anti-digoxin 26-10 (sFv')2 and anti-
c-erbB-2 741F8 (sFv')2 made by protein folding and bonded through
carboxyl-terminal cysteinyl peptides. Protein Eng. 8:301-314.
Neri, D., M. Momo, T. Prospero, and G. Winter. 1995. Hign-affinity
antigen binding by chelating recombinant antibodies (CRAbs). J. Mol.
Biol. 246:367-373.
Novotny, J., R. Bruccoleri, J. Newell, D. Murphy, E. Haber, and M.
Karplus. 1983. Molecular anatomy of the antibody binding site. J. Biol.
Chem. 258:14433-14437.
Novotny, J., R. E. Bruccoleri, and F. A. Saul. 1989. On the attribution of
binding energy in antigen-antibody complexes McPC603, DI.3, and
HyHEL-5 Biochemistry. 28:4735-4749.
Novotny, J., and E. Haber. 1985. Structural invariants of antigen binding:
comparison of immunoglobulin VL-VH and VL-VL domain dimers. Proc.
Natl. Acad. Sci. USA. 82:4592-4596.
Poljak, R. J., L. M. Amzel, H. P. Avey, B. L. Chen, R. P. Phizackerley, and
F. Saul. 1973. Structure of Fab' NEW at 2.8 A resolution. Proc. Natl.
Acad. Sci. USA. 70:3305-3310.
Predki, P. F., V. Agrawal, A. T. Briinger, and L. Regan. 1996. Amino-acid
substitutions in a surface turn modulate protein stability. Nature Struct.
Biol. 3:54-58.
Quinn, T. P., N. B. Tweedy, R. W. Williams, J. S. Richardson, and D. C.
Richardson. 1994. Betadoublet: de novo design, synthesis, and charac-
terization of a P3-sandwich protein. Proc. Natl. Acad. Sci. USA. 91:
8747-8751.
Reichmann, L., J. Foote, and G. Winter. 1988. Expression of an antibody
Fv fragment in myeloma cells. J. Mol. Biol. 203:825-828.
Sandlie, I., B. Bogen, and E. Lunde. 1996. Antigen presentation of a T cell
epitope inserted at different positions in an antibody heavy chain. Key-
stone Symposium, Taos, NM, February 22-28. 47.
Satow, Y., G. Cohen, E. A. Padlan, and D. R. Davies. 1986. Phosphocho-
line binding immunoglobulin Fab McPC 603, an x-ray diffraction study
at 2.7 A. J. Mol. Biol. 190:593-604.
Searle, S. J., J. T. Pedersen, A. H. Henry, D. M. Webster, and A. R. Rees.
1995. Antibody structure and function. In Antibody Engineering, 2nd ed.
C. Borrebaeck, editor. Oxford University Press, New York and Oxford.
3-51.
Segal, D. M., E. A. Padlan, G. H. Cohen, S. Rudikoff, M. Potter, and D. R.
Davies. 1974. The three-dimensional structure of a phosphorylcholine-
binding mouse immunoglobulin Fab and the nature of the antigen
binding site. Proc. Natl. Acad. Sci. USA. 71:4298-4302.
Simon, T., and K. Rajewsky. 1992. A functional antibody mutant with an
insertion in the framework region 3 loop of the VH domain: implications
for antibody engineering. Protein Eng. 5:229-234.
Skerra, A., and A. Pluckthun. 1988. Assembly of a functional immuno-
globulin Fv fragment in Escherichia coli. Science. 240:1038-1041.
Tai, M-S, J. E. McCartney, G. P. Adams, D. Jin, R. M. Hudziak, H.
Oppermann, A. A. Laminet, M. A. Bookman, S. Liu, W. F. Stafford III,
I. Fand, L. L. Houston, L. M. Weiner, and J. S. Huston. 1995. Targeting
c-erbB-2 expressing tumors using single-chain Fv monomers and
dimers. Cancer Res. 55(Suppl.):5983s-5989s.
Tai, M.-S., M. Mudgett-Hunter, D. Levinson, G.-M. Wu, E. Haber, H.
Oppermann, and J. S. Huston. 1990. A bifunctional fusion protein
containing Fc-binding fragment B of Staphylococcal protein A amino
terminal to antidigoxin single-chain Fv. Biochenmistry. 29:8024-8030.
Verhoeyen, M., C. Milstein, and G. Winter. 1988. Reshaping human
antibodies: grafting an antilysozyme activity. Science. 239:1534-1536.
Winter, G., A. D. Griffiths, R. E. Hawkins, and H. R. Hoogenboom. 1994.
Making antibodies by phage display technology. Annu. Rev. Immunol.
12:433-455.
Xiong, H., B. L. Buckwalter, H.-M. Shieh, and M. H. Hecht. 1995.
Periodicity of polar and nonpolar amino acids is the major determinant
of secondary structure in self-assembling oligomeric peptides. Proc.
Natl. Acad. Sci. USA. 92:6349-6353.
Yan, Y., and B. W. Erickson. 1994. Engineering of betabellin 14D:
disulfide-induced folding of a ,3-sheet protein. Protein Sci.
3:1069-1073.
